Discounted Cash Flow
Indivior Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2021 | $791.0m | $205.0m | $338.0m | 25.9% | $1.41 |
| 2022 | $901.0m (13.9%) | $-53.0m (-125.9%) | $-17.0m (-105.0%) | -5.9% (-122.7%) | $-0.38 (-127.0%) |
| 2023 | $1.1b (21.3%) | $2.0m (103.8%) | $-334.0m (-1864.7%) | 0.2% (103.1%) | $0.01 (102.6%) |
| 2024 | $1.2b (8.7%) | $2.0m (0.0%) | $7.0m (102.1%) | 0.2% (-8.0%) | $0.02 (100.0%) |
| 2025 | $1.2b (4.3%) | $210.0m (10400.0%) | $-93.0m (-1428.6%) | 16.9% (9967.8%) | $1.68 (8300.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.